Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Lx2020
LXEO•FDA designates LX2020 as RMAT for PKP2 arrhythmogenic cardiomyopathy
Aug. 5 (Reuters) - Lexeo Therapeutics, Inc. LXEO.O:
- Lexeo Therapeutics receives FDA regenerative medicine advanced therapy (RMAT) designation for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy
- Lexeo Therapeutics receives FDA regenerative medicine advanced therapy (RMAT) designation for LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy
- Lexeo Therapeutics says LX2020 holds RMAT, orphan drug, and fast track designations from FDA
